infection in many individuals no overt symptoms are observed, CMV came to medical attention due to its significant morbidity and mortality associated with congenital infec- Clinical evaluation of active and passive immunisation strategies against CMV in the context of congenital CMV
Although following primary human cytomegalovirus (CMV)
infection in many individuals no overt symptoms are observed, CMV came to medical attention due to its significant morbidity and mortality associated with congenital infec- 
Subunit vaccines
Another vaccine strategy is based on a subunit vaccine that was A prospective study carried out in mothers with confirmed primary infection demonstrated that monthly intravenous administration of HIG can decrease mother-to-fetus transmission significantly, from 40% to 16% and the risk of congenital disease from 50% to 3% 21 . Several retrospective studies have suggested that CMV HIG can reduce intrauterine transmission of CMV 22 and can protect against poor outcomes in infants 23, 24 . However, in a recent randomised trial, HIG treatment did not significantly modify the course of primary CMV infection during the pregnancy 25 . Therefore, in our perspective more randomised studies are required to draw a firm conclusion on the efficacy of HIG therapy.
CMV vaccines in preclinical studies
Several However, the safety and immunogenicity of these vaccine candi-
dates is yet to be determined in advanced clinical studies in the context of congenital CMV.
Extensive studies in humans have revealed that the gH/gL/ UL128-131A pentameric complex is the most important antigenic complex for neutralising antibodies especially to restrict the entry of CMV into epithelial and endothelial cells 30 . High titers of neutralising antibodies are thought to protect against transmission by blocking receptor-mediated transplacental transmission of CMV and by reducing viral replication 31, 32 . Therefore, it will be interesting to investigate the potential role of pentameric glycoprotein complex-specific humoral responses in both primary and recurrent infections in pregnant women.
Major barriers in the development of effective CMV vaccines
Conventional CMV vaccine approaches that target a single genotype may induce only partial protection due to high levels of CMV Under the Microscope Comprehensive analysis of CMV genotypes, CMV-specific NK cell immunity, neutralising antibody, effector and memory CD4+ and CD8+
T cell responses
Apply this knowledge to identify correlates of protection and vaccine design Figure 1 . Proposed method for screening and understanding the magnitude of protective immune responses during pregnancy. A large cohort of young women before and after pregnancy should be screened for cytomegalovirus (CMV) status. Regular monitoring of CMV-specific immune responses should be carried out using several comprehensive analysis approaches and pregnancy outcomes after long-term follow-up should be related to the magnitude of the immune response observed during the study. This knowledge can be used for the development of a potent CMV vaccine.
